SEARCH
CONNECT
NATIONAL RESILIENCE
- Safety Inquiries
- Terms of Service
- Privacy Policy
- Cookie Settings
- © 2025 National Resilience, Inc. All Rights Reserved
Extraordinary goals call for extraordinary collaborations. By linking our collective insights and capabilities, we can push through the unknown to deliver better pathways to healthcare.
Parvus is developing a pipeline of novel Navacim™ therapeutic candidates which generate disease-specific Treg cells in vivo to reverse autoimmune disease without impairing normal immune function.
A strategic collaboration to advance rare disease programs using Be Bio’s proprietary engineered B Cell Medicines (BCMs) platform. Be Bio and Resilience are investing in programs to drive innovation and reliability in cell therapy manufacturing, a critical success factor for broad and meaningful patient impact. Be Bio is harnessing the power of the human B cell to create a new class of cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning.
Resilience and BridgeBio have a strategic multi-year partnership focused on advancing future gene therapy treatments, where Resilience will manufacture BridgeBio’s lead investigational gene therapy treatments.
Resilience has been named a launch Industry Resource Partner by CIRM and is providing access to its GMP biomanufacturing services for CIRM Translational and Clinical Stage projects.
PICI is working to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.
A next-generation manufacturing R&D collaboration, and expense- and revenue-sharing model for successfully commercialized oncology products.
Learn more about Mayo Clinic’s Center for Regenerative Medicine here.
.png?width=1634&height=442&name=MicrosoftTeams-image%20(3).png "LabCorp Logo")
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint All-Domain Operations. JPEO- CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment.
The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats.
To learn more about the JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow the JPEO-CBRND on social media @JPEOCBRND.
Disclaimer: The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government, and shall not be used for advertising or product endorsement purposes. The mention of companies by name is solely for the purpose of representing Command collaborations, and should not be implied as an endorsement.
Harvard and Resilience established a five-year R&D alliance in 2021, directed toward the development of complex medicines, including biologics, vaccines, nucleic acids and cell and gene therapies.